Biotech Values

[mcbio]

Good to see this after the Euro trial didn't look so good for Dacogen compared to Vidaza. I'm high on SUPG (who gets royalties on sales of Dacogen) but want to wait to see what this quarter's Dacogen sales look like to see if the Euro trial has caused any further erosion in Dacogen sales.

Regardless, the fact that SUPG gets at least 20% in royalties on the drug is a great thing for a tiny biotech (about $100 million market cap) like SUPG, especially in this market. And hopefully this new trial will cast a better light on Dacogen.